{"code":"C101255","name":"Aldosterone Receptor Antagonist","terminology":"ncit","version":"26.08e","conceptStatus":"DEFAULT","leaf":false,"active":true,"synonyms":[{"name":"Aldosterone inhibitor (mineralocorticoid receptor antagonist)","termType":"PT","type":"FULL_SYN","typeCode":"P90","source":"ACC/AHA","code":"VAR","subSource":"SARS2"},{"name":"Aldosterone Receptor Antagonist","termType":"PT","type":"FULL_SYN","typeCode":"P90","source":"NCI"},{"name":"Antimineralocorticoid","termType":"SY","type":"FULL_SYN","typeCode":"P90","source":"NCI"},{"name":"Aldosterone Receptor Antagonist","type":"Preferred_Name","typeCode":"P108"}],"definitions":[{"definition":"A class of agents that act by selectively inhibiting aldosterone receptor activation with diuretic activity. Aldosterone receptor antagonists bind to and block the activation of aldosterone (mineralocorticoid) receptors on the epithelial cells in the late distal tubule and collecting duct of the kidney, thus preventing the synthesis of aldosterone-induced proteins which enhance Na+ retention and K+ and H+ secretion. The enhanced excretion of Na+ produces diuresis ultimately resulting in a reduction in blood pressure without the loss of K+.","code":"P97","type":"DEFINITION","source":"NCI"},{"definition":"Spironolactone or eplerenone, which antagonize the action of aldosterone at mineralocorticoid receptors","code":"P325","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"code":"P381","type":"attribution","value":"SARS2"}]}],"properties":[{"code":"P322","type":"Contributing_Source","value":"ACC/AHA"},{"code":"P106","type":"Semantic_Type","value":"Chemical Viewed Functionally"},{"code":"P207","type":"UMLS_CUI","value":"C3536833"}],"children":[{"code":"C171675","name":"Apararenone","leaf":true},{"code":"C77555","name":"Azolimine","leaf":true},{"code":"C83582","name":"Canrenone","leaf":true},{"code":"C77558","name":"Clazolimine","leaf":true},{"code":"C174699","name":"Dicirenone","leaf":true},{"code":"C47513","name":"Eplerenone","leaf":true},{"code":"C169981","name":"Finerenone","leaf":true},{"code":"C223831","name":"Furterene Formate","leaf":true},{"code":"C65791","name":"Furterene","leaf":true},{"code":"C84118","name":"Prorenoate Potassium","leaf":true},{"code":"C84117","name":"Prorenoate","leaf":true},{"code":"C840","name":"Spironolactone","leaf":true},{"code":"C152420","name":"Spirorenone","leaf":true},{"code":"C152421","name":"Spiroxasone","leaf":true}],"parents":[{"code":"C2355","name":"Anti-Adrenal"}],"associations":[{"code":"A8","type":"Concept_In_Subset","relatedCode":"C191200","relatedName":"ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology"},{"code":"A8","type":"Concept_In_Subset","relatedCode":"C191670","relatedName":"ACC/AHA COVID-19 Appendix Variables"},{"code":"A8","type":"Concept_In_Subset","relatedCode":"C191387","relatedName":"Appendix 8: Pharmacological Therapy Terminology"},{"code":"A48","type":"Has_ACC-AHA_SARS2_Authorized_Value","relatedCode":"C49487","relatedName":"No"},{"code":"A8","type":"Concept_In_Subset","relatedCode":"C191405","relatedName":"Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission) Terminology"},{"code":"A48","type":"Has_ACC-AHA_SARS2_Authorized_Value","relatedCode":"C17998","relatedName":"Unknown"},{"code":"A48","type":"Has_ACC-AHA_SARS2_Authorized_Value","relatedCode":"C49488","relatedName":"Yes"}],"history":[{"code":"C101255","action":"create","date":"2012-04-09"},{"code":"C101255","action":"modify","date":"2012-12-10"},{"code":"C101255","action":"modify","date":"2017-12-26"},{"code":"C101255","action":"modify","date":"2019-05-28"},{"code":"C101255","action":"modify","date":"2021-08-30"},{"code":"C101255","action":"modify","date":"2021-10-25"},{"code":"C101255","action":"modify","date":"2022-12-27"},{"code":"C101255","action":"modify","date":"2023-02-27"},{"code":"C101255","action":"modify","date":"2026-02-23"}]}